NH2

Total Synthesis of Entecavir

Javier Velasco,^{†,‡} Xavier Ariza,^{*,†,§} Laura Badía,[‡] Martí Bartra,[‡] Ramon Berenguer,[‡] Jaume Farràs,^{*,†} Joan Gallardo,[†] Jordi Garcia,^{†,§} and Yolanda Gasanz[‡]

[†]Departament de Química Orgànica and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Facultat de Química, Universitat de Barcelona, Martí i Franquès 1, 08028-Barcelona, Spain

[‡]R&D Department, Esteve Química S.A., Caracas 17-19, 08030-Barcelona, Spain

[§]CIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain

Supporting Information

ABSTRACT: Entecavir (BMS-200475) was synthesized from 4-trimethylsilyl-3-butyn-2-one and acrolein. The key features of its preparation are: (i) a stereoselective boron—aldol reaction to afford the acyclic carbon skeleton of the methylenecylopentane moiety; (ii) its cyclization by a Cp₂TiCl-catalyzed intramolecular radical addition of an epoxide to an alkyne; and (iii) the coupling with a purine derivative by a Mitsunobu reaction.


■ INTRODUCTION

B-type hepatitis is a global disease. It is one of the most common viral infections worldwide despite an efficient vaccine being available since 1982. According to the World Health Organization (WHO), about two billion people are infected worldwide and 600 000 die every year due to consequences such as cirrhosis of the liver or liver cancer. Hepatitis B can manifest itself in both acute and chronic forms and is especially dangerous in children. About 90% of infants infected during the first year of life develop chronic infections, although this ratio drops to 30-50% in children infected between the ages of one and four. About 25% of adults who become chronically infected during childhood will die from hepatitis B-related liver cancer or cirrhosis while about 90% of people who become infected during adulthood will recover and be completely free of the virus within six months. About 240 million people are thought to be chronically infected with the disease worldwide.¹

In its chronic form, hepatitis B can be treated with interferon or antiviral agents. The most frequently used antiviral agents against hepatitis B virus (HBV) are entecavir (1), tenofovir, adefovir, telbivudine, and lamivudine (Figure 1).²

Of these, entecavir is considered one of the best choices for the treatment of chronic patients due to its lack of significant adverse effects and the low risk of inducing long-term resistance to the drug.³

Entecavir (BMS-200475), first synthesized by Bristol-Myers Squibb,⁴ was identified as a potent inhibitor of HBV in vitro $(ED_{50} = 3 \text{ nM})^5$ and was later commercialized as Baraclude. Its patent is due to expire in 2015 in the U.S. and soon afterward in other countries. In anticipation of the availability of a generic version, a plethora of patent applications has appeared recently.^{6,8a,b} Most of the reported synthetic approaches for the stereoselective construction of the cyclopentane framework are based on transformation of a cyclopentane moiety,^{6,7} and only a few start with an acyclic precursor that is subsequently cyclized.⁸ In this paper, we disclose a concise synthesis of 1



нò

Entecavir

Figure 1. Antiviral agents used against HBV.

TMS

from acyclic precursors.⁹ As shown in Scheme 1, the retrosynthetic analysis of this carbocyclic nucleoside¹⁰ takes advantage of the ability of epoxides to act as effective precursors of radicals. The key step involves the Ti(III)-mediated generation of a β -alkoxy carbon radical¹¹ from epoxide 4 that can cyclize to a methylene cyclopentane 5 through the cyclic transition state shown in Figure 2.

It is worth noting that the proposed radical cyclization has been reported previously in a failed attempt to prepare **1**. Thus, Ziegler¹² prepared epoxide **4b** (PG₁ = PG₂ = TBS) from protected D-glucose in 9 steps and reported very good cyclization yields when **4b** was treated with 3 equiv of Cp₂TiCl₂ in the presence of an excess of Zn in THF. Considering these precedents, we implemented an alternative route to epoxides **4** where the key step is an enantioselective acetate aldol addition¹³ of methyl ketone **2** to acrolein followed by the *in situ* reduction of the corresponding β -hydroxy ketone.

 Received:
 March 22, 2013

 Published:
 May 16, 2013

Scheme 1





Figure 2. Proposed TS for the radical cyclization of 4.

This approach drastically reduces the number of steps involved and potentially provides more flexibility with respect to the election of protecting groups (PG_1 and PG_2).

RESULTS AND DISCUSSION

The enantioselective aldol reaction of 4-trimethylsilyl-3-butyn-2-one (2) with acrolein was carried out using (+)-chlorodiisopinocampheylborane ((+)-DIPCl) as a source of chirality.¹⁴ As shown in Scheme 2, the *in situ* reduction of the resulting


Scheme 2



chelate¹⁵ with LiBH₄ followed by an oxidative work up provided **3a** (PG₁ = PG₂ = H) as a mixture of diols in 66% yield and moderate selectivity (80:20 er, 90:10 *syn/anti* ratio) after chromatography. It is worth noting that recrystallization from hexanes afforded pure *syn* diol **3a** (98% er, >99% dr) in 37% overall yield. Despite the low yield, this method is very straightforward and allows the skeleton of the cyclization precursor **4** to be constructed from easily available commercial starting materials in a one-pot procedure.

Conversion of **3a** into the Ziegler's epoxide **4b** or its TMSderivative **6** is very efficient (Scheme 3). Unfortunately, the cyclization of **4b** leads to the methylene cyclopentane **5b** (PG₁ = PG₂ = TBS, PG₃ = H, Scheme 1) where the differentiation of TBS ethers would be problematic during the introduction of Article





the nucleobase. On the other hand, our preliminary attempts at the cyclization of epoxide **6** led to the complete degradation of the starting material. With a view to circumventing these limitations, we evaluated the cyclization reactions for a series of epoxides of type **4** with different protecting groups (Scheme 1, $PG_1 \neq PG_2$).

Preparation of 4 ($PG_1 \neq PG_2$) from 3a or 7a is not trivial in some cases because there is no reliable information in the literature on the selective monoprotection of secondary propargylic alcohols in the presence of secondary allylic ones. In order to establish the viability of the monoprotection reactions, a set of silvlations and benzoylations were carried out on these diols. Table 1 summarizes the optimized conditions found for each substrate and highlights the fact that protection of the propargylic position is clearly favored over the protection of the corresponding allylic position. Moderate-to-good yields of the desired monoprotected diol can be achieved while at the same time maintaining the yields of diprotected byproducts below 15%. Yields of the monoprotected allylic alcohol are less than 5%.

On the basis of these results, we attempted to prepare the diprotected epoxides 4g-j (Scheme 4) through selective monoprotection of 3a followed by the removal of the TMS group to afford 7c-e monoalcohols. The sequence was completed by epoxidation with *m*-CPBA and final protection of the remaining alcohol. The alternative pathway, in which the epoxidation was the final step, was less convenient since the epoxidation of protected allylic alcohols is slow, and it is even slower with acetylated allylic alcohols. On the other hand, for the preparation of 4k via 7f removal of the TMS group of 3a to afford diol 7a was the first step in the sequence since this deprotection was not compatible with a benzoate group.


With epoxides 4g-k in hand, we attempted to bring about their Ti(III)-mediated cyclization by treatment with Cp₂TiCl₂ in the presence of an excess of a metal M such as Zn or Mn (Scheme 5). In this type of reaction the metal reduces Cp_2TiCl_2 to a Cp_2TiCl radical (8). Reaction of 8 with the corresponding epoxide 4 generates the titanocene(IV) β -alkoxy carbon radical 9 that gives rise to a cyclic vinyl radical 10. This radical can then be quenched either by a hydrogen donor or by another Ti(III) radical to afford 11 or 12 (X = H or Cp_2TiCl_1 respectively). Protonolysis of 11/12 should give methylene cyclopentane 5. Although this reaction can be catalytic in Cp₂TiCl₂, Ziegler¹² described the cyclization of epoxide 4b using an excess of Cp₂TiCl₂. Under these conditions, however, we could not reproduce the reported yield. When epoxide 4b was treated with Cp₂TiCl₂ in the presence of an excess of Zn following the described procedure, the methylene cyclopropane

Table 1. Monoprotection of Diols 3a and 7a

$\begin{array}{c} \textbf{3a} \ (\text{R} = \text{TMS}) \\ \textbf{7a} \ (\text{R} = \text{H}) \end{array} \qquad \qquad \begin{array}{c} \text{R'Cl} \ (1.2 \ \text{equiv}) \\ \hline \text{Base, rt} \end{array} \qquad \qquad \qquad \begin{array}{c} \text{R'Q} \qquad \text{OH} \\ \hline \text{R} \end{array}$								
entry	diol	R	R′	base	solvent	<i>t</i> (h)	yield (product)	
1^a	3a	TMS	TBS	Imidazole	THF	5	65% (3c)	
2	3a	TMS	TBDPS	Imidazole	THF	5	62% (3d)	
3	3a	TMS	TIPS	Imidazole	THF	15	69% (3e)	
5 ^a	7a	Н	TBS	Imidazole	CH_2Cl_2	5	54% (7c)	
6 ^{<i>a</i>}	7a	Н	Bz	DIPEA	CH_2Cl_2	15	86% (7f)	


^aR'Cl (1.1 equiv) was added.





(a) **3c**, **3d** or **3e**, K₂CO₃ (0.25-0.5 equiv), MeOH, 1-3 h, rt, **7c**: 99%, **7d**: 84%, **7e**: 95%; (b) **7c-f**, *m*-CPBA (2.5-6.0 equiv), CH₂Cl₂, 2.5-15 h, rt, **4c**: 97%, **4d**: 99%, **4e**: 95%, **4f**: 87%; (c) **4c** or **4e**, Ac ₂O (1.*c* equiv), NEt₃, CH₂Cl₂, 1 h, rt, **4g**: 98%, **4**]: 90%; (d) **4c**, TBDPSCI (2.0 equiv), imidazole, THF, rt, **48** h, **4h**: 79%; (e) **4d** or **4f**, TBSCI (1.9-2.6 equiv), imidazole, THF, rt, 24 h, **4i**: 71%, **4k**: 67%.

Scheme 5



5b ($PG_1 = PG_2 = TBS$, $PG_3 = H$) was obtained with good diastereoselectivity but in a yield of only 30%.

Fortunately, yields could be increased to 50% by replacing the aqueous H_2SO_4 workup with a treatment with saturated NH_4Cl (entry 1, Table 2). Under these optimized conditions,

Table 2. Stoichiometric Cyclization of Propargylic Epoxides 4b and 4g-k

$\begin{array}{c} \text{RO} & \text{OR'} \\ \hline \\ \textbf{4b-k} \end{array} \xrightarrow{(Cp_2\text{TiCl}_2 (3 \text{ equiv}))} \\ \text{THF, 15 h, rt} \end{array} \qquad \begin{array}{c} \text{HO} \\ \text{RO} \xrightarrow{(V)} \\ \text{RO} \xrightarrow{(V)} \\ \text{Sb-k} \end{array}$								
entry	epoxide	R	R′	product	yield (%)	dr^a		
1	4b	TBS	TBS	5b	50	95:5		
2	4h	TBS	TBDPS	5h	43	>97:3		
3	4i	TBDPS	TBS	5i	<10 ^a	n.d.		
4	4k	Bz	TBS	5k	49	90:10		
5	4g	TBS	Ac	5g	40	96:4		
6	4j	TIPS	Ac	5j	0			
^a Not chromatographically isolated. Yield estimated from ¹ H NMR.								

cyclizations of epoxides 4g-k were carried out. The results are summarized in Table 2 and it can be seen that the election of the propargylic alcohol protecting group (R) is critical. TBS provided the best yields (entries 1, 2, and 5) when compared with TIPS and TBDPS (entries 3 and 6) and better selectivity than the benzoyl group (entry 4). In sharp contrast, protection of the allylic alcohol has little effect on yield or selectivity (entries 1, 2, and 5). These results suggested 4b, 4g and 4h to be the most promising candidates for cyclization. We finally chose the transformation of 4g to 5g as the key step of the synthesis because it provided better overall yield from diol 3a and allowed differentiation of the protected alcohols.

The Ti-catalytic version of the cyclization was also explored in an attempt to improve the process. In the stoichiometric process 11/12 are cleaved in the final step by treatment with saturated NH₄Cl. In the catalytic version an alternative proton source is required to cleave 11/12 and regenerate the catalyst. Gansäuer¹⁶ described the use of collidine hydrochloride as the most convenient reagent for doing so.

After careful optimization of the reaction conditions we were able to carry out the cyclization of 4g to 5g using 20% catalyst and collidine hydrochloride as proton source with excellent selectivity and comparable yields to the stoichiometric version (Table 3, entries 1 and 4). Mn provides similar yields to Zn but requires less metal to generate 8.

On the other hand, we found that the use of trimethylsilylcollidinium chloride¹⁷ instead of collidine hydrochloride (entries 2 and 5) while not improving yields did improve the reproducibility of the process at larger scales. A further improvement was achieved by introducing Vaska's

Tabl	le 3.	Cata	lytic	Су	vclization	of	4g 1	to	Cycl	lopenta	ne 5g
------	-------	------	-------	----	------------	----	------	----	------	---------	-------


	4g	Collidine HCI (3 equiv collidine (8 equiv) / TM IrCI(CO)(PPh ₃) ₂ / H ₂ () or MSCI (4 equiv)	
entry	М	THF, 4 h, rt collidinium salt	IrCl(CO)(PPh ₃) ₂	yield (%)
1	Zn	Collidine·HCl		36
2	Zn	Collidine/TMSCl		38
3	Zn	Collidine/TMSCl	5%	51
4	Mn	Collidine·HCl		42
5	Mn	Collidine/TMSCl		36
6	Mn	Collidine/TMSCl	5%	49
7	Mn	Collidine/TMSCl	10%	58

complex, $IrCl(CO)(PPh_3)_2$ in the presence of H_2 as hydrogen donor¹⁸ (entries 3, 6, and 7).

The last step in the preparation of the carbocyclic moiety of Entecavir was the protection of the primary hydroxyl group of 5g in the form of a *p*-nitrobenzoyl ester 5l. The election of this protecting group is important because 5l can be crystallized and purified. By this means, chromatographic purifications of intermediates 3a to 5g (which are oils) can be avoided (Scheme 6).

Final conversion of **5**1 to pharmaceutical-grade Entecavir was straightforward. Selective acidic deprotection of the TBS ether

Scheme 6



(a) TBSCI (1.1 equiv), imidazole, THF, 6 h, rt, 69%; (b) K_2CO_3 cat., MeOH, 1 h, rt, 95%; (c) *m*-CPBA, CH₂Cl₂, 15 h, rt, 95%; (d) Ac₂O, NEt₃, DMAP cat., CH₂Cl₂, 1 h, rt, 95%; (e) Cp₂TiCl₂ 20% mol., IR(CIO()(PPh₃)₂ 10% mol., MR (2 equiv), collidine, TMSCI, H₂ (4 bar), THF, 4 h, rt, 58%; (f) *p*-O₂NBZCI, NEt₃, CH₂Cl₂, 1.5 h, rt, 74%. (g) 5% (+)-CSA, MeOH, 3 h, rt, 89%. (h) 2-amino-6-chloropurine, DIAD, PPh₃, THF, 3 h, -10 °C, 61%. (i) HCOOH, 50 °C, 9h, 92%. (j) MeONa, MeOH, 1 h, rt, 72%.

followed by Mitsunobu reaction with 2-amino-6-chloropurine^{6x} led to the chloroderivative 13 that was transformed into protected Entecavir 14 by treatment with formic acid. Saponification of 14 then gave Entecavir of pharmaceutical grade. Reversal of the order of the last two steps decreased the overall yield and increased the formation of impurities that impeded the crystallization of the final product as did the direct acid hydrolysis of both of the esters and the chloropurine moiety.

CONCLUSIONS

A straightforward synthesis of Entecavir was achieved in 11 steps from commercially available starting materials. The cyclopentane skeleton was prepared from acyclic precursors by a boron-aldol reaction and a Ti(III)-catalyzed cyclization of an epoxide to an alkyne as key steps. The carbocylic structure obtained in this way was attached to a purine moiety by a Mitsunobu reaction. It is worth mentioning that the use of the p-nitrobenzoyl group in the final steps allows purification by crystallization thus avoiding chromatography and making the synthesis amenable to scale-up. The selective hydrolysis of the 6-chloropurine unit with formic acid is also essential in order to facilitate the crystallization of the final product.

EXPERIMENTAL SECTION

All reactions involving moisture- or air-sensitive reagents were performed in oven-dried glassware under N₂. Chemical shifts (δ) were quoted in parts per million and referenced for ¹H NMR to internal TMS (for CDCl₃) or residual solvent peak δ 2.50 ppm (for DMSO- d_6). ¹³C NMR was referenced to CDCl₃ (δ 77.0 ppm) or DMSO- d_6 (δ 39.5 ppm). Column chromatography was performed on silica gel (Merck 230–400 mesh). HRMS analyses were recorded on a LC/MSD-TOF mass spectrometer.

(3S,5R)-7-(Trimethylsilyl)hept-1-en-6-yne-3,5-diol (3a). NEt₂ (11.60 mL, 85 mmol) was added to a stirred solution of (+)-DIPCl (90-105%) (25.000 g, 78 mmol) in anhydrous THF (40 mL) under N₂ at 0 °C. 4-Trimethylsilyl-3-butyn-2-one (98%, 9.78 g, 70 mmol) was added dropwise and the mixture was stirred for 2 h at -5 to 0 °C. The solution was cooled to -78 °C and a solution of acrolein (90%, 7.62 mL, 103 mmol) in anhydrous THF (20 mL) was added slowly and the mixture was stirred for 1 h at $-78\,$ °C. A 2 M solution of LiBH₄ in hexanes (53 mL, 106 mmol) was added slowly and the mixture was stirred for a further 1 h at -78 °C. After careful quenching with saturated NH₄Cl (40 mL) at -78 °C the mixture was allowed to warm to rt over 30 min. After partitioning between H₂O (40 mL) and MTBE (90 mL) the aqueous layer was extracted with MTBE (25 mL). The organic phases were combined and dried (MgSO₄). Solvent removal afforded a pale yellow oil (62 g). THF/H₂O (3:1, 80 mL) was added under $N_{\rm 2}$ at rt followed by NaOAc (4.40 g, 54 mmol) and the mixture was cooled to 0 °C. $\rm H_2\dot{O}_2$ (30%, 30 mL, 5 equiv) was added dropwise over 10 min and the mixture was stirred for a further 10 min at 0 $^\circ C$ and 30 min at rt. After cooling to 0 $^\circ C$ a saturated solution of Na₂S₂O₃ (30 mL) was added slowly and the mixture was stirred for 10 min at 0 °C and 15 min at rt. H₂O (20 mL) and MTBE (35 mL) were added and the organic phase was decanted. The aqueous layer was extracted with MTBE (10 mL) and the combined organic extracts were dried (MgSO₄). Solvent removal gave a clear oil (49.2 g) that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 60:40 (gradient elution)] to give 9.130 g of a mixture of diols (er 80:20; syn/anti 90:10).

Recrystallization from hexanes afforded the product as a white crystalline solid (3a, 9a 5.2 g, 37% overall yield, er 98%). Mp 80–82 °C. [α]_D²⁵ +2.3 (*c* 1.0, CHCl₃). IR (film): 3349, 2956, 2922, 2899, 2176 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.90 (ddd, *J* = 17.2, 10.4, 5.9 Hz, 1H), 5.29 (ddd, *J* = 17.2, 1.4, 1.3 Hz, 1H), 5.14 (ddd, *J* = 10.4, 1.4, 1.3 Hz, 1H), 4.64 (dd, *J* = 7.9, 5.2 Hz, 1H), 4.43–4.37 (m, 1H), 2.80 (bs, 1H), 2.46 (bs, 1H), 2.03–1.89 (m, 2H), 0.18 (s, 9H). ¹³C NMR

The Journal of Organic Chemistry

(CDCl₃, 101 MHz): δ 140.1, 115.1, 106.1, 89.9, 72.1, 62.0, 44.0, -0.1. HRMS (ESI): m/z calcd for $C_{10}H_{18}O_2SiNa^+$ [M + Na]⁺ 221.0969; found 221.0974.

(3S,5R)-3,5-Bis(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yne (3b). A solution of TBSCl (0.800 g, 5.30 mmol) in anhydrous CH₂Cl₂ (5 mL) was added dropwise to a solution of diol 3a (0.500 g, 2.52 mmol) and imidazole (0.377 g, 5.54 mmol) in anhydrous CH₂Cl₂ (5 mL) at 0 °C under N₂. The mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH4Cl (5 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was extracted with CH_2Cl_2 (5 mL). The organic phase was dried (MgSO₄) and the solvent was removed affording an oil that was purified by flash chromatography (silica gel, hexanes-AcOEt 95:5) to give 1.030 g (96%) of the title compound^{9a} (3b) as a yellow oil. $[\alpha]_D^{25}$ +21.6 (c 1.0, CHCl₃). IR (film): 3071, 2952, 2930, 2897, 2858, 2172 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz): δ 5.81 (ddd, J = 17.2, 10.3, 6.4 Hz, 1H), 5.15 (dt, J = 17.2, 1.4 Hz, 1H), 5.04 (dt, J = 10.3, 1.4 Hz, 1H), 4.46 (dd, J = 7.7, 6.4 Hz, 1H), 4.33-4.24 (m, 1H), 1.90 (ddd, J = 13.2, 8.1)6.7 Hz, 1H), 1.74 (ddd, J = 13.2, 7.7, 5.2 Hz, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.16 (s, 9H), 0.13 (s, 3H), 0.10 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 141.3, 114.4, 107.4, 89.5, 71.3, 61.3, 46.9, 26.0, 25.9, 18.4, 18.3, 0.0, -4.1, -4.3, -4.8, -4.8. HRMS (ESI): m/z calcd for $C_{22}H_{47}O_2Si_3^+$ [M + H]⁺ 427.2878; found 427.2867

(3S,5R)-5-(tert-Butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3c). A solution of TBSCI (4.180 g, 27.73 mmol) in anhydrous THF (20 mL) was added dropwise to a solution of diol 3a (5.000 g, 25.21 mmol) and imidazole (2.060 g, 30.25 mmol) in anhydrous THF (60 mL) at 0 °C under N2, and the mixture was allowed to warm to rt and was stirred for 5 h. A 22% solution of NH₄Cl (25 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the organic phase was dried (MgSO₄) and the solvent was removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 97:3 to 80:20 (gradient elution)] to give 5.123 g (65%) of the title compound^{9a} (3c) as a pale yellow oil. $[\alpha]_D^{25}$ +39.9 (c 1.0, CHCl₃). IR (film): 3424, 3081, 2958, 2930, 2898, 2858, 2172 cm⁻¹. ¹H NMR $(CDCl_3, 300 \text{ MHz}): \delta 5.86 \text{ (ddd, } J = 17.2, 10.5, 5.6 \text{ Hz}, 1\text{H}), 5.28 \text{ (dt, } J = 17.2, 10.5, 5.6 \text{ Hz}, 1\text{H})$ *J* = 17.2, 1.5 Hz, 1H), 5.11 (dt, *J* = 10.5, 1.5 Hz, 1H), 4.59 (dd, *J* = 7.9, 5.3 Hz, 1H), 4.42-4.30 (m, 1H), 2.98 (d, J = 2.4 Hz, 1H), 1.99-1.86 (m, 2H), 0.91 (s, 9H), 0.19 (s, 3H), 0.16 (s, 12H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.3, 114.6, 106.7, 90.3, 71.5, 62.9, 45.1, 25.9, 18.2, -0.2, -4.1, -4.8. HRMS (ESI): m/z calcd for $C_{16}H_{33}O_2Si_2^+$ [M + H]⁺ 313.2014; found 313.2005.

(35,5R)-5-(tert-Butyldiphenylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3d). TBDPSCI (1.57 mL, 6.10 mmol) was added dropwise to a solution of diol 3a (1.000 g, 5.04 mmol) and imidazole (0.481 g, 7.06 mmol) in anhydrous THF (9.5 mL) at 0 °C under N_{24} and the mixture was allowed to warm to rt and was stirred for 5 h. A 22% solution of NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the organic phase was dried (MgSO₄), and the solvent was removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 95:5 to 90:10 (gradient elution)] to give 1.363 g (62%) of the title compound (3d) as a pale yellow oil. $[\alpha]_D^{25}$ +62.5 (*c* 1.0, CHCl₃). IR (film): 3446, 3071, 2958, 2931, 2894, 2857 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 7.77-7.66 (m, 4H), 7.45-7.33 (m, 6H), 5.84 (ddd, J = 17.2, 10.5, 5.6 Hz, 1H), 5.23 (dt, J = 17.2, 1.5 Hz, 1H), 5.07 (dt, J = 10.5, 1.5 Hz, 1H), 4.54 (t, J = 6.3 Hz, 1H), 4.51-4.43 (m, 1H),2.64 (d, J = 3.4 Hz, 1H), 2.01–1.85 (m, 2H), 1.06 (s, 9H), 0.10 (s, 9H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.4, 136.2, 136.0, 134.9, 133.6, 133.3, 130.0, 129.8, 129.7, 127.8, 127.7, 127.5, 114.5, 106.2, 91.3, 70.6, 62.8, 45.2, 27.0, 26.7, 19.4, -0.4. HRMS (ESI): m/z calcd for $C_{26}H_{37}O_2Si_2^+$ [M + H]⁺ 437.2327; found 437.2325

(35,5R)-5-(Triisopropylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3e). TIPSCI (5.20 mL, 30.25 mmol) was added dropwise to a solution of diol 3a (5.000 g, 25.21 mmol) and imidazole (2.230 g, 32.77 mmol) in anhydrous THF (40 mL) at 0 °C under N₂, and the mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH₄Cl (20 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the organic phase was extracted with MTBE (2 × 20 mL). The combined organic phases were dried (MgSO₄), and the solvent was removed affording an oil that was purified by flash chromatography [silica gel, hexanes–AcOEt, from 97:3 to 80:20 (gradient elution)] to give 6.173 g (69%) of the title compound as a pale yellow oil. $[\alpha]_D^{25}$ +23.5 (*c* 0.6, CHCl₃). IR (film): 3421, 3074, 2944, 2894, 2867, 2167 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz): δ 5.89 (ddd, *J* = 17.2, 10.5, 5.6 Hz, 1H), 5.28 (dt, *J* = 17.2, 1.5 Hz, 1H), 5.11 (dt, *J* = 10.5, 1.5 Hz, 1H), 4.71 (t, *J* = 6.4 Hz, 1H), 4.49–4.41 (m, 1H), 2.92 (d, *J* = 2.7 Hz, 1H), 1.95–1.89 (m, 2H), 1.27–1.13 (m, 3H), 1.13–1.04 (m, 18H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.5, 114.4, 106.9, 90.3, 71.1, 62.5, 45.5, 18.2, 17.9, 12.5, -0.2. HRMS (ESI): *m*/*z* calcd for C₁₉H₃₉O₂Si₂⁺ [M + H]⁺ 355.2483; found 355.2478.

(35,5*R*)-Hept-1-en-6-yne-3,5-diol (7a). K₂CO₃ (0.348 g, 2.52 mmol) was added in one portion to a stirred solution of 3a (1.000 g, 5.04 mmol) in anhydrous MeOH (10 mL) at rt under N₂. The mixture was then stirred for 1 h. A buffer solution (pH = 7, 10 mL) and CH₂Cl₂ (10 mL) were added, the mixture was partitioned and the organic phase was dried (MgSO₄). Solvent removal gave the title compound (7a)¹² as a yellow oil 0.628 g (98%). [*a*]_D²⁵ +5.8 (*c* 1.0, CHCl₃). IR (film): 3347, 3290, 3060, 2983, 2953, 2922, 2887, 2113 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.86 (ddd, *J* = 17.2, 10.4, 6.0 Hz, 1H), 5.26 (dt, *J* = 17.2, 1.4 Hz, 1H), 5.11 (dt, *J* = 10.4, 1.4 Hz, 1H), 4.61 (ddd, *J* = 8.3, 5.1, 2.1 Hz, 1H), 4.41–4.34 (m, 1H), 2.75 (bs, 1H), 2.49 (d, *J* = 2.1 Hz, 1H), 2.35 (bs, 1H), 2.03–1.84 (m, 2H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.1, 115.2, 84.5, 73.3, 72.0, 61.3, 43.9. HRMS (ESI): *m*/*z* calcd for C₇H₁₀NaO₂⁺ [M + Na]⁺ 149.0573; found 149.0572.

(3S,5R)-3,5-Bis(tert-butyldimethylsilyloxy)hept-1-en-6-yne (7b). A solution of TBSCI (2.059 g, 13.60 mmol) in anhydrous CH₂Cl₂ (5 mL) was added dropwise to a solution of diol 7a (0.820 g, 6.50 mmol) and imidazole (1.062 g, 15.60 mmol) in anhydrous CH₂Cl₂ (3 mL) at 0 °C under N₂, and the mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was extracted with CH_2Cl_2 (2 \times 10 mL). The combined organic phases were dried (MgSO₄) and the solvent was removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 97:3 to 80:20 (gradient elution)] to give 2.280 g (95%) of the title compound $(7b)^1$ as a pale yellow oil. $[\alpha]_D^{25}$ +13.0 (c 1.0, CHCl₃). IR (film): 3306, 3093, 2958, 2930, 2887, 2858 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.81 (ddd, J = 17.2, 10.4, 6.5 Hz, 1H), 5.17 (dt, J = 17.2, 1.2 Hz, 1H), 5.05 (dt, J = 10.4, 1.2 Hz, 1H), 4.47 (ddd, J = 8.2, 6.5, 2.0 Hz, 1H), 4.33–4.26 (m, 1H), 2.42 (d, J = 2.0 Hz, 1H), 1.99–1.74 (m, 2H), 0.91 (s, 9H), 0.90 (s, 9H), 0.14 (s, 3H), 0.11 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 141.3, 114.4, 85.4, 72.9, 71.1, 60.6, 47.2, 26.0, 25.9, 18.4, 18.3, -4.1, -4.4, -4.8, -4.9. HRMS (ESI): m/z calcd for $C_{19}H_{39}O_2Si_2^+$ [M + H]⁺ 355.2483; found 355.2486.

(35,5*R*)-5-(*tert*-Butyldimethylsilyloxy)hept-1-en-6-yn-3-ol (7c). K₂CO₃ (0.101 g, 0.73 mmol) was added in one portion to a stirred solution of 3c (0.455 g, 1.46 mmol) in anhydrous MeOH (4.5 mL) at rt under N₂ and the mixture was stirred for 1 h. After solvent removal CH₂Cl₂ (10 mL) was added to the residue and the solution was filtered and dried (MgSO₄). Solvent removal gave the title compound (7c)^{9a} as a pale yellow oil (0.366 g, 99%). $[\alpha]_D^{25}$ +32.7 (*c* 1.0, CHCl₃). IR (film): 3417, 3311, 3079, 2956, 2930, 2886, 2858, 2109 cm⁻¹. (CDCl₃, 300 MHz): δ 5.88 (ddd, *J* = 17.2, 10.4, 5.7 Hz, 1H), 5.29 (dt, *J* = 17.2, 1.5 Hz, 1H), 5.12 (dt, *J* = 10.4, 1.5 Hz, 1H), 4.61 (ddd, *J* = 7.8, 5.8, 2.1 Hz, 1H), 4.42–4.33 (m, 1H), 2.71 (d, *J* = 2.7 Hz, 1H), 2.47 (d, *J* = 2.1 Hz, 1H), 2.03–1.85 (m, 2H), 0.92 (s, 9H), 0.19 (s, 3H), 0.16 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.3, 114.8, 84.9, 73.5, 71.2, 62.0, 45.2, 25.9, 18.2, -4.2, -4.9. HRMS (ESI): *m/z* calcd for C₁₃H₂₄NaO₂Si⁺ [M + Na]⁺ 263.1438; found 263.1431.

(35,5R)-5-(*tert*-Butyldiphenylsilyloxy)hept-1-en-6-yn-3-ol (7d). K₂CO₃ (0.080 g, 0.57 mmol) was added in one portion to a stirred solution of 3d (0.500 g, 1.14 mmol) in anhydrous MeOH (5 mL) at rt under N₂ and the mixture was stirred for 3 h. A buffer solution (pH = 7, 5 mL) and MTBE (15 mL) were added, the mixture was partitioned and the organic phase was dried (MgSO₄). Solvent removal gave the title compound (7d) as a pale yellow oil (0.350 g, 84%). $[\alpha]_D^{25}$ +34.3 (*c* 1.0, CHCl₃). IR (film): 3453, 3303, 3071, 2956, 2930, 2891, 2858 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 7.78–7.69 (m, 4H), 7.47–7.36 (m, 6H), 5.88–5.78 (m, 1H), 5.22 (dt, *J* = 17.2, 1.4 Hz, 1H), 5.08 (dt, *J* = 10.5, 1.4 Hz, 1H), 4.60 (td, *J* = 6.5, 2.1 Hz, 1H), 4.47–4.39 (m, 1H), 2.35 (d, *J* = 2.1 Hz, 1H), 2.15 (m, 1H), 1.96–1.90 (m, 2H), 1.10 (s, 9H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.5, 136.2, 136.0, 133.3, 133.3, 130.4, 129.9, 127.8, 127.6, 114.6, 84.5, 74.2, 70.3, 62.1, 45.3, 27.0, 19.4. HRMS (ESI): *m/z* calcd for C₂₃H₂₈NaO₂Si⁺ [M + Na]⁺ 387.1751; found 387.1752.

(35,5*R*)-5-(Triisopropylsilyloxy)hept-1-en-6-yn-3-ol (7e). K₂CO₃ (0.526 g, 3.81 mmol) was added in one portion to a stirred solution of 3e (6.000 g, 15.23 mmol) in anhydrous MeOH (50 mL) at rt under N₂ and the mixture was stirred for 1 h. A buffer solution (pH = 7, 15 mL) and MTBE (15 mL) were added, the mixture was partitioned and the organic phase was dried (MgSO₄). Solvent removal gave the title compound (7e) as a pale yellow oil (4.084 g, 95%). $[\alpha]_D^{25}$ +15.7 (*c* 1.0, CHCl₃). IR (film): 3421, 3311, 3083, 2944, 2893, 2867 cm^{-1.} ¹H NMR (CDCl₃, 300 MHz): δ 5.97–5.83 (m, 1H), 5.29 (ddd, *J* = 17.3, 2.7, 1.4 Hz, 1H), 5.12 (ddd, *J* = 10.4, 2.6, 1.4 Hz, 1H), 4.74 (td, *J* = 6.7, 2.1 Hz, 1H), 4.50–4.39 (m, 1H), 2.55 (d, *J* = 3.0 Hz, 1H), 2.49–2.46 (m, 1H), 1.99–1.91 (m, 2H), 1.24–1.06 (m, 21H). ¹³C NMR (CDCl₃, 101 MHz): δ 140.5, 114.6, 85.0, 73.6, 70.9, 61.8, 45.5, 18.2, 18.1, 17.8, 12.4. HRMS (ESI): *m/z* calcd for C₁₆H₃₁O₂Si⁺ [M + H]⁺ 283.2088; found 283.2077.

(3R,5S)-5-Hydroxyhept-6-en-1-yn-3-yl benzoate (7f). i-Pr₂NEt (0.76 mL, 4.37 mmol) was added dropwise to a solution of 7a (0.460 g, 3.64 mmol) in anhydrous CH₂Cl₂ (9 mL) at 0 °C under N2. BzCl (0.46 mL, 3.96 mmol) was added dropwise at 0 °C and the mixture was warmed to rt and stirred for 15 h. MeOH (2 mL) was added and the mixture was stirred for 10 min. After solvent removal the resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 80:20 (gradient elution)] to give the title compound (7f, as the major isomer in a 91:9 mixture of monobenzoylated regioisomers) as a pale yellow oil (0.741 g, 86%). $\left[\alpha\right]_{D}^{25}$ +26.0 (c 1.0, CHCl₃). IR (film): 3467, 3294, 3071, 2959, 2928, 2885, 2121, 1719 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.11-8.03 (m, 2H), 7.63-7.54 (m, 1H), 7.50-7.41 (m, 2H), 5.93 (ddd, J = 17.1)10.4, 6.0 Hz, 1H), 5.79 (ddd, J = 7.6, 6.5, 2.2 Hz, 1H), 5.30 (dt, J = 17.1, 1.2 Hz, 1H), 5.17 (dt, J = 10.4, 1.2 Hz, 1H), 4.53-4.42 (m, 1H), 2.56 (d, J = 2.2 Hz, 1H), 2.30–2.05 (m, 2H). ¹³C NMR (CDCl₃, 101 MHz): δ 165.4, 140.0, 133.4, 129.9, 129.8, 128.5, 115.5, 81.0, 74.7, 69.9, 62.2, 41.7. HRMS (ESI): m/z calcd for $C_{14}H_{14}NaO_3^+$ [M + Na]⁺ 253.0835; found 253.0837.

(1S,3R)-1,3-Bis(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)-5-(trimethylsilyl)pent-4-yne (6). A solution of 3b (0.900 g, 2.11 mmol) in anhydrous CH_2Cl_2 (5 mL) was added to a suspension of m-CPBA (77%, 1.417 g, 6.32 mmol) in anhydrous CH₂Cl₂ (10 mL) at rt under N2 and the mixture was stirred at rt for 15 h. The mixture was filtered and the organic phase was washed with saturated Na₂S₂O₃ (5 mL), saturated NaHCO₃ (10 mL), dried (MgSO₄) and the solvent was removed to give the title compound (6) as a yellow oil (0.853 g, 91%). IR (film): 3048, 2956, 2929, 2887, 2857 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 4.61–4.54 (m, 1H), 3.88 (ddd, J = 6.5, 6.4, 4.2 Hz, 0.4H), 3.49 (ddd, J = 8.7, 7.0, 4.5 Hz, 0.6H), 3.00-2.92 (m, 1H), 2.83-2.76 (m, 0.6H), 2.70-2.64 (m, 0.8H), 2.56 (dd, J = 4.9, 2.7 Hz, 0.6H), 2.02-1.80 (m, 2H), 0.92-0.90 (m, 18H), 0.16-0.08 (m, 21H). ¹³C NMR (CDCl₃, 101 MHz): δ 106.8, 106.7, 90.1, 90.0, 72.7, 68.4, 61.2, 61.1, 56.0, 54.8, 45.2, 44.3, 43.7, 43.2, 26.0, 25.9, 18.4, 18.3, 0.0, -0.1, -4.2, -4.4, -4.5, -4.8, -4.9, -5.1. HRMS (ESI): m/z calcd for $C_{22}H_{47}O_3Si_3^+$ [M + H]⁺ 443.2828; found 443.2827.

(15,3R)-1,3-Bis(*tert*-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yne (4b). A solution of 7b (2.260 g, 6.37 mmol) in anhydrous CH₂Cl₂ (5 mL) was added to a suspension of *m*-CPBA (77%, 3.180 g, 19.12 mmol) in anhydrous CH₂Cl₂ (25 mL) at rt under N₂ and the mixture was stirred at rt for 15 h. The mixture was filtered and the organic phase was washed with saturated Na₂S₂O₃ (10 mL), saturated NaHCO₃ (2 × 10 mL), dried (MgSO₄) and the solvent was removed to give an oily residue that was purified by flash chromatography [silica gel, hexanes–AcOEt, from 90:10 to 50:50 (gradient elution)] to give the title compound (**4b**)¹² as a pale yellow oil (2.240 g, 95%). IR (film): 3311, 3045, 2954, 2928, 2886, 2857 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz): δ 4.58 (m, 1H), 3.83 (dd, *J* = 7.8, 4.7 Hz, 0.4H), 3.49 (ddd, *J* = 8.7, 6.9, 4.3 Hz, 0.6H), 2.97 (ddd, *J* = 6.9, 4.1, 2.7 Hz, 0.6H), 2.93 (ddd, *J* = 4.5, 3.9, 2.7 Hz, 0.4H), 2.79 (dd, *J* = 4.8, 4.2 Hz, 0.6H), 2.72–2.64 (m, 0.8H), 2.57 (dd, *J* = 4.9, 2.7 Hz, 0.6H), 2.43 (d, *J* = 2.1 Hz, 0.4H), 2.41 (d, *J* = 2.1 Hz, 0.6H), 2.06–1.79 (m, 2H), 0.92–0.88 (m, 18H), 0.16–0.06 (m, 12H). ¹³C NMR (CDCl₃, 101 MHz): δ 85.0, 84.9, 73.3, 73.3, 72.4, 68.6, 60.5, 56.0, 54.7, 45.1, 44.7, 44.1, 43.5, 26.1, 26.0, 25.9, 18.4, 18.3, 18.2, -4.2, -4.5, -4.9, -5.0, -5.1. HRMS (ESI): *m*/*z* calcd for C₁₉H₃₉O₃Si₂⁺ [M + H]⁺ 371.2432; found 371.2425.

(15,3R)-3-(tert-Butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4**yn-1-ol (4c).** A suspension of *m*-CPBA (77%, 13.640 g, 60.83 mmol) in anhydrous CH₂Cl₂ (30 mL) at rt under N₂ was added to a stirred solution of 7c (5.849 g, 24.33 mmol) in anhydrous CH₂Cl₂ (20 mL) and the mixture was stirred at rt for 15 h. The mixture was filtered and the organic phase was washed with saturated $Na_2S_2O_3$ (35 mL), saturated NaHCO₃ (2×15 mL), dried (MgSO₄) and the solvent was removed to give the title compound $(4c)^{9a}$ as a yellow oil (6.048 g, 97%). IR (film): 3454, 3318, 3083, 2962, 2930, 2895, 2860 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 4.58-4.54 (m, 1H), 3.89-3.83 (m, 0.4H), 3.72-3.65 (m, 0.6 H), 2.95 (ddd, J = 8.0, 4.1, 2.0 Hz, 1H), 2.71–2.63 (m, 2H), 2.38 (d, J = 2.1 Hz, 0.4H), 2.47 (d, J = 2.1 Hz, 0.6H), 1.98-1.81 (m, 2H), 0.81 (s, 9H), 0.08 (s, 1.2H), 0.08 (s, 1.8H), 0.06 (s, 1.2H), 0.05 (s, 1.8H). ¹³C NMR (CDCl₃, 101 MHz): δ 84.5, 84.4, 73.6, 73.5, 69.7, 68.2, 61.7, 61.3, 55.2, 54.3, 44.9, 44.4, 42.4, 41.9, 25.8, 18.2, 18.1, -4.3, -4.4, -5.0, -5.1. HRMS (ESI): m/z calcd for $C_{13}H_{25}O_3Si^+$ [M + H]⁺ 257.1568; found 257.1559.

(15,3R)-3-(tert-Butyldiphenylsilyloxy)-1-(oxiran-2-yl)pent-4yn-1-ol (4d). A suspension of *m*-CPBA (77%, 0.516 g, 2.26 mmol) in anhydrous CH_2Cl_2 (3 mL) at rt under N_2 was added to a stirred solution of 7d (0.275 g, 0.754 mmol) in anhydrous CH₂Cl₂ (2 mL) and the mixture was stirred at rt for 2.5 h. After filtration the organic phase was washed with saturated $Na_2S_2O_3$ (5 mL), saturated $NaHO_3$ $(2 \times 15 \text{ mL})$ and dried (MgSO₄). Solvent removal gave the title compound (4d) as a pale yellow oil (0.290 g, 99%). IR (film): 3447, 3287, 2960, 2930, 2891, 2857, 2117 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 7.77–7.66 (m, 4H), 7.47–7.35 (m, 6H), 4.67–4.59 (m, 1H), 4.10-4.04 (m, 0.4H), 3.84-3.76 (s, 0.6H), 3.05 (dd, J = 6.6, 3.7 Hz, 0.4H), 2.98 (td, J = 4.3, 2.8 Hz, 0.6H), 2.79–2.68 (m, 2H), 2.37 (d, J = 2.1 Hz, 1H), 2.02–1.85 (m, 3H), 1.08 (s, 9H). ¹³C NMR (CDCl₃, 101 MHz): δ 136.2, 136.1, 135.9, 133.2, 133.2, 133.2, 130.10, 130.1, 130.0, $127.9,\ 127.8,\ 127.6,\ 127.5,\ 84.1,\ 84.1,\ 74.3,\ 74.2,\ 68.8,\ 66.7,\ 61.9,\ 61.7,$ 55.2, 54.4, 45.0, 43.9, 42.7, 41.7, 27.0, 19.4. HRMS (ESI): m/z calcd for $C_{23}H_{28}NaO_3Si^+$ [M + Na]⁺ 403.1700; found 403.1702.

(15,3*R*)-1-(Oxiran-2-yl)-3-(triisopropylsilyloxy)pent-4-yn-1-ol (4e). A solution of 7e (4.900 g, 17.34 mmol) in anhydrous CH₂Cl₂ (7 mL) was added to a suspension of *m*-CPBA (77%, 9.500 g, 42.48 mmol) in anhydrous CH₂Cl₂ (33 mL) at rt under N₂ and the mixture was stirred at rt for 15 h. After filtration the organic phase was washed with saturated Na₂S₂O₃ (20 mL), saturated NaHCO₃ (2 × 20 mL) and dried (MgSO₄). Solvent removal gave the title compound (4e)^{9a} as a pale yellow oil (4.920 g, 95%). IR (film): 3447, 3310, 2944, 2867, 2109 cm^{-1.} ¹H NMR (CDCl₃, 400 MHz): δ 4.80–4.74 (m, 1H), 4.09–4.02 (m, 0.4H), 3.87–3.79 (m, 0.6H), 3.11–3.04 (m, 1H), 2.84–2.79 (m, 1H), 2.78–2.74 (m, 1H), 2.49 (d, *J* = 2.1 Hz, 0.4H), 2.47 (d, *J* = 2.1 Hz, 0.6H), 2.10–1.91 (m, 2H), 1.13–1.04 (m, 21H). ¹³C NMR (CDCl₃, 101 MHz): δ 84.7, 84.6, 73.6, 73.6, 69.5, 67.5, 61.5, 61.2, 55.4, 54.4, 45.0, 44.2, 42.8, 42.1, 18.1, 18.1, 12.4, 12.3. HRMS (ESI): *m*/*z* calcd for C₁₆H₃₁O₃Si⁺ [M + H]⁺ 299.2037; found 299.2035.

(3R,5S)-5-Hydroxy-5-(oxiran-2-yl)pent-1-yn-3-yl Benzoate (4f). A solution of 7f (0.500 g, 2.17 mmol, 91:9 mixture of monobenzoylated regioisomers) in anhydrous CH₂Cl₂ (3 mL) was added to a suspension of *m*-CPBA (77%, 1.460 g, 6.51 mmol) in anhydrous CH₂Cl₂ (2 mL) at rt under N₂ and the mixture was stirred at rt for 15 h. After filtration the organic phase was washed with

The Journal of Organic Chemistry

saturated Na₂S₂O₃ (7 mL), saturated NaHCO₃ (2 × 10 mL) and dried (MgSO₄). Solvent removal gave an oily residue that was purified by flash chromatography [silica gel, hexanes–AcOEt, from 90:10 to 50:50 (gradient elution)] to give the title compound (4f) as a pale yellow oil (0.465 g, 87%, single monobenzoylated regioisomer). IR (film): 3446, 3288, 3063, 2997, 2929, 2121, 1719 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.07–8.01 (m, 2H), 7.60–7.53 (m, 1H), 7.44 (t, *J* = 7.7 Hz, 2H), 5.89–5.81 (m, 1H), 4.18 (ddd, *J* = 7.9, 4.8, 3.3 Hz, 0.4H), 3.86 (dt, *J* = 9.0, 4.6 Hz, 0.6H), 3.09 (ddd, *J* = 7.4, 6.0, 2.9 Hz, 1H), 2.88–2.81 (m, 1H), 2.79–2.74 (m, 0.6H), 2.72 (dd, *J* = 5.0, 4.0 Hz, 0.4H), 2.56 (t, *J* = 1.9 Hz, 1H), 2.32–2.13 (m, 2H). ¹³C NMR (CDCl₃, 101 MHz): δ 165.4, 133.5, 133.4, 129.9, 129.9, 129.6, 129.6, 128.6, 128.5, 80.7, 80.6, 74.9, 74.8, 68.5, 65.9, 62.1, 62.0, 55.1, 54.2, 45.1, 43.7, 39.3, 38.4. HRMS (ESI): *m/z* calcd for C₁₄H₁₅O₄⁺ [M + H]⁺ 247.0965; found 247.0966.

(15,3R)-3-(tert-Butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4ynyl Acetate (4g). NEt₃ (3.80 mL, 27.89 mmol) was added dropwise to a solution of 4c (5.499 g, 21.45 mmol) and a catalytic amount of DMAP in anhydrous CH₂Cl₂ (50 mL) at 0 °C under N₂. Ac₂O (2.40 mL, 25.74 mmol) was added dropwise at 0–5 $^\circ C$ and the mixture was allowed to warm to rt and stirred for 1 h. Saturated NH₄Cl (35 mL) was added slowly and the mixture was stirred for 10 min. After partitioning the aqueous phase was extracted with CH₂Cl₂ (20 mL) and the combined organic phases were washed with saturated NaHCO₃ (30 mL). The aqueous phase was extracted with CH₂Cl₂ (20 mL) and the combined organic phases were dried (MgSO₄) and the solvent was removed to give the title compound^{9a} (4g) as a pale yellow oil (6.300 g, 98%). IR (film): 3295, 3075, 2970, 2947, 2903, 2873, 1750 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.07–4.99 (m, 1H), 4.54-4.48 (m, 1H), 3.16 (ddd, J = 5.7, 4.1, 2.6 Hz, 0.6H), 3.05 (ddd, J = 4.9, 3.9, 2.7 Hz, 0.4H), 2.82 (dd, J = 4.9, 4.2 Hz, 0.6H), 2.77-2.70 (m, 0.8H), 2.67 (dd, J = 4.8, 2.7 Hz, 0.6H), 2.44 (d, J = 2.1 Hz, 0.6H), 2.43 (d, J = 2.1 Hz, 0.4H), 2.08 (s, 1.2H), 2.06 (s, 1.8H), 2.16-1.97 (m, 2H), 0.90 (s, 9H), 0.15 (s, 1.8H), 0.14 (s, 1.2H), 0.12 (s, 1.8H), 0.12 (s, 1.2H). ¹³C NMR (CDCl₃, 101 MHz): δ 171.1, 85.1, 74.5, 74.4, 72.0, 70.9, 60.8, 54.1, 53.2, 46.3, 40.9, 40.7, 26.8, 22.1, 22.0, 19.2, -3.5, -4.1. HRMS (ESI): m/z calcd for $C_{15}H_{27}O_4Si^+$ [M + H]⁺ 299.1674; found 299.1665.

(5R,7S)-5-Ethynyl-2,2,3,3,10,10-hexamethyl-7-(oxiran-2-yl)-9,9-diphenyl-4,8-dioxa-3,9-disilaundecane (4h). TBDPSCl (0.17 mL, 0.66 mmol) was added dropwise to a solution of 4c (0.085 g, 0.33 mmol) and imidazole (0.050 g, 0.73 mmol) in anhydrous THF (3 mL) at 0 $^\circ\text{C}$ under N_2 , and the mixture was warmed to 30 $^\circ\text{C}$ and stirred for 48 h. A 22% solution of NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. MTBE (15 mL) and H₂O (5 mL) were added and the mixture was stirred for 10 min and partitioned. The organic phase was dried (MgSO₄), and the solvent was removed. The resulting oily residue was purified by flash chromatography (silica gel, hexanes-AcOEt 98:2) to give the title compound (4h) as a colorless oil (0.130 g, 79%). IR (film): 3309, 3049, 2956, 2930, 2892, 2857 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 7.73–7.68 (m, 4H), 7.44–7.32 (m, 6H), 4.70 (ddd, J = 7.6, 6.9, 2.1 Hz, 0.4H), 4.57 (dt, J = 6.8, 2.1 Hz, 0.6H), 3.69-3.57 (m, 1H), 3.11-3.04 (m, 0.6H), 2.90-2.84 (m, 0.4H), 2.67 (dd, J = 4.8, 4.3 Hz, 0.6H), 2.46 (dd, J = 4.9, 2.7 Hz, 0.6H), 2.32–2.28 (m, 0.6H), 2.20 (d, J = 2.1 Hz, 0.4H), 1.99 (m, 1H), 1.91-1.82 (m, 1H), 1.08 (s, 9H), 0.85 (s, 9H), 0.12 (s, 0.6H), 0.09 (s, 2.4H), 0.07 (s, 0.6H), 0.07 (s, 2.4H). ¹³C NMR (CDCl₃, 101 MHz): δ 136.2, 136.1, 136.1, 136.0, 134.0, 133.8, 133.7, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.7, 127.7, 127.5, 85.1, 84.7, 73.1, 73.0, 72.9, 71.3, 60.1, 60.0, 55.6, 54.5, 46.5, 45.2, 44.6, 43.5, 27.2, 27.1, 25.9, 25.8, 19.6, 19.5, 18.3, 18.2, -4.4, -4.5, -4.9. HRMS (ESI): m/z calcd for $C_{29}H_{46}NO_{3}Si_{2}^{+}[M + NH_{4}]^{+}$ 512.3011; found 512.3005.

(5*R*,7*S*)-5-Ethynyl-2,2,9,9,10,10-hexamethyl-7-(oxiran-2-yl)-3,3-diphenyl-4,8-dioxa-3,9-disilaundecane (4i). A solution of TBSCl (0.230 g, 1.53 mmol) in anhydrous THF (2 mL) was added dropwise to a solution of 4d (0.220 g, 0.58 mmol) and imidazole (0.110 g, 1.62 mmol) in anhydrous THF (3 mL) at 0 °C under N₂, and the mixture was warmed to 30 °C and stirred for 24 h. A 22% solution of NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. MTBE (15 mL) and H₂O (5 mL) were added and the mixture was stirred for 10 min and partitioned. The organic phase was dried (MgSO₄), and the solvent was removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 99:1 to 90:10 (gradient elution)] to give the title compound (4i) as a colorless oil (0.203 g, 71%). IR (film): 3307, 3071, 2955, 2928, 2892, 2856 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz): δ 7.89-7.78 (m, 4H), 7.60-7.46 (m, 6H), 4.71-4.62 (m, 1H), 3.93 (dt, *I* = 8.0, 4.1 Hz, 0.3H), 3.64–3.54 (m, 0.7H), 3.07–2.96 (m, 1H), 2.88 (dd, *J* = 4.8, 4.2 Hz, 0.7H), 2.80 (dd, *J* = 5.4, 4.2 Hz, 0.3H), 2.74 (dd, *J* = 5.4, 2.8 Hz, 0.3H), 2.66 (dd, J = 4.9, 2.8 Hz, 0.7H), 2.50 (d, J = 2.1 Hz, 0.3H), 2.48 (d, I = 2.1 Hz, 0.7H), 2.20–2.00 (m, 2H), 1.22 (bs, 9H), 0.87 (bs, 6H), 0.84 (s, 3H), 0.19 (s, 2H), 0.14 (s, 1H), 0.11 (s, 1H), 0.04 (s, 2H).¹³C NMR (CDCl₃, 101 MHz): δ 136.2, 136.1, 135.9, 135.9, 133.5, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.8, 127.6, 127.5, 84.5, 84.4, 74.1, 74.0, 72.4, 68.6, 61.8, 56.0, 54.7, 45.0, 44.7, 43.6, 43.0, 27.0, 25.9, 25.9, 19.4, 18.1, 18.1, -4.4, -4.3, -5.1, -5.3. HRMS (ESI): m/z calcd for $C_{29}H_{42}NaO_3Si_2^+$ [M + Na]⁺ 517.2565; found 517.2572.

(1S,3R)-1-(Oxiran-2-yl)-3-(triisopropylsilyloxy)pent-4-yn-1-yl Acetate (4j). NEt₃ (0.29 mL, 2.15 mmol) was added dropwise to a solution of 4e (0.495 g, 1.66 mmol) and a catalytic amount of DMAP in anhydrous CH₂Cl₂ (5 mL) at 0 °C under N₂. Ac₂O (0.19 mL, 1.99 mmol) was added dropwise at 0 $^\circ\mathrm{C}$ and the mixture was allowed to warm to rt and stirred for 1 h. Saturated NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. After partitioning the aqueous phase was extracted with CH₂Cl₂ (5 mL) and the organic phases were combined and washed with saturated NaHCO₂ (2×5) mL). The combined organic phases were dried (MgSO₄), and solvent removal gave the title compound (4j) as a yellow oil (0.508 g, 90%). IR (film): 3301, 3064, 2944, 2867, 2118 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.12–5.06 (m, 1H), 4.64–4.55 (m, 1H), 3.17 (ddd, J = 5.6, 4.2, 2.7 Hz, 0.6H), 3.07 (ddd, J= 4.4, 3.7, 2.6 Hz, 0.4H), 2.83 (dd, J=4.9, 4.2 Hz, 0.6H), 2.75 (m, 0.8H), 2.68 (dd, I = 4.9, 2.6 Hz, 0.6H), 2.44 (m, 1H), 2.15–1.99 (m, 5H), 1.18–0.98 (m, 21H). ¹³C NMR (CDCl₃, 101 MHz): δ 170.1, 84.1, 73.5, 73.4, 70.9, 69.8, 60.0, 59.9, 53.2, 52.2, 45.3, 40.2, 39.7, 21.0, 20.9, 18.1, 18.0, 17.8, 12.4, 12.3, 12.2. HRMS (ESI): m/z calcd for $C_{18}H_{33}O_4Si^+$ [M + H]⁺ 341.2143; found 341.2141

(3R,5S)-5-(tert-Butyldimethylsilyloxy)-5-(oxiran-2-yl)pent-1yn-3-yl Benzoate (4k). A solution of TBSCl (0.464 g, 3.08 mmol) in anhydrous THF (2 mL) was added dropwise to a solution of 4f (0.400 g, 1.62 mmol) and imidazole (0.330 g, 4.86 mmol) in anhydrous THF (3 mL) at 0 °C under N₂, and the mixture was warmed to 30 °C and stirred for 24 h. A 22% solution of NH₄Cl (5 mL) was added slowly and the mixture was stirred for 10 min. MTBE (15 mL) and H_2O (5 mL) were added and the mixture was stirred for 10 min and partitioned. The organic phase was dried (MgSO₄), and the solvent was removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 95:5 to 90:10 (gradient elution)] to give the title compound (4k) as a white waxy solid (0.390 g, 67%). IR (film): 3270, 3066, 2954, 2928, 2886, 2856, 2121, 1724 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz): δ 8.09-8.03 (m, 2H), 7.62-7.53 (m, 1H), 7.48-7.41 (m, 2H), 5.83-5.75 (m, 1H), 3.90 (dt, J = 7.4, 4.6 Hz, 0.3H), 3.60 (ddd, J = 8.7, 6.8, 4.4 Hz, 0.7H), 3.02–2.80 (m, 1H), 2.70-2.66 (m, 0.6H), 2.53 (m, 1.4H), 2.29-2.18 (m, 1H), 2.14-2.03 (m, 1H), 0.93 (bs, 9H), 0.16 (s, 1.5H), 0.14 (s, 3H), 0.09 (s, 1.5H). $^{13}{\rm C}$ NMR (CDCl₃, 101 MHz): δ 165.3, 165.2, 133.4, 133.4, 129.9, 129.8, 129.7, 128.6, 128.5, 80.8, 74.8, 74.7, 72.0, 68.6, 62.1, 61.8, 55.7, 54.5, 45.2, 45.0, 40.1, 39.6, 26.0, 25.9, 18.2, -4.2, -4.3, -4.9, -5.1. HRMS (ESI): m/z calcd for $C_{20}H_{32}NO_4Si^+$ [M + NH₄]⁺ 378.2095; found 378.2099.

General Procedure for Noncatalytic 5-Exo Cyclization. Strictly deoxygenated anhydrous THF (76 mL) was added to a mixture of Cp₂TiCl₂ (1.711 g, 6.87 mmol) and activated Zn powder (1.800 g, 27.48 mmol) under N₂ and the suspension was stirred at rt until it turned lime green. This suspension was then added slowly to a solution of 4b (0.850 g, 2.29 mmol) over 3 h and the mixture was stirred for 15 h at rt. A 22% solution of NH₄Cl (60 mL) was added slowly and the mixture was stirred for 2 h, filtered and the solvent was removed. AcOEt (100 mL) was added and the mixture was stirred for

10 min. The mixture was partitioned and the aqueous phase was extracted with AcOEt (2×50 mL). The combined organic phases were dried (MgSO₄) and the solvent was removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes–AcOEt, from 95:5 to 80:20 (gradient elution)] to give the title compound as a pale yellow oil (0.424 g, 50%).

([1*R*,3*R*,5*S*)-3,5-Bis(*tert*-butyldimethylsilyloxy)-2-methylenecyclopentyl)methanol (5b).¹² [*α*]_D²⁵ -30.4 (*c* 1.0, CHCl₃). IR (film): 3460, 3070, 2956, 2930, 2887, 2858 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.21 (t, *J* = 2.3 Hz, 1H), 5.01 (t, *J* = 2.3 Hz, 1H), 4.33 (ddd, *J* = 9.3, 4.8, 2.3 Hz, 1H), 4.00 (ddd, *J* = 10.1, 8.0, 6.2 Hz, 1H), 3.82-3.69 (m, 2H), 2.66-2.59 (m, 1H), 2.24 (dd, *J* = 11.6, 6.2 Hz, 1H), 1.67-1.61 (m, 1H), 0.92 (s, 9H), 0.89 (s, 9H), 0.10 (s, 3H), 0.09 (s, 6H), 0.08 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 152.1, 108.4, 72.4, 71.0, 63.0, 53.2, 43.9, 26.0, 25.9, 18.4, 18.1, -4.1, -4.4, -4.6, -4.7. HRMS (ESI): *m*/*z* calcd for C₁₉H₄₁O₃Si₂⁺ [M + H]⁺ 373.2589; found 373.2592.

(15,2*R*,4*R*)-4-(*tert*-Butyldimethylsilyloxy)-2-hydroxymethyl-3-methylenecyclopentyl acetate (5g).^{9a} $[α]_D^{25}$ -43.5 (*c* 1.0, CHCl₃). IR (film): 3462, 3083, 2955, 2930, 2887, 2858, 1734 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 5.24 (t, *J* = 2.3 Hz, 1H), 5.1 (t, *J* = 2.3 Hz, 1H), 4.99 (dt, *J* = 8.4, 6.4 Hz, 1H), 4.42 (m, 1H), 3.70 (d, *J* = 5.8 Hz, 2H), 2.84–2.73 (m, 1H), 2.48–2.38 (m, 1H), 2.07 (s, 3H), 1.81– 1.69 (m, 1H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 171.9, 151.7, 109.0, 73.5, 72.7, 63.7, 51.0, 40.5, 25.9, 21.3, 18.3, -4.5, -4.7. HRMS (ESI): *m/z* calcd for C₁₅H₂₉O₄Si⁺ [M + H]⁺ 301.1830; found 301.1816.

((1*R*,3*R*,55)-3-(*tert*-Butyldimethylsilyloxy)-5-(*tert*-butyldiphenylsilyloxy)-2-methylenecyclopentyl)methanol (5h). $[\alpha]_D^{25}$ -18.3 (*c* 1.0, CHCl₃). IR (ATR): 3454, 3070, 2955, 2929, 2888, 2856 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 7.73–7.65 (m, 4H), 7.47–7.35 (m, 6H), 5.17 (t, *J* = 2.3 Hz, 1H), 4.99 (t, *J* = 2.3 Hz, 1H), 4.18–4.09 (m, 1H), 4.02 (dt, *J* = 9.5, 6.7 Hz, 1H), 3.60 (dd, *J* = 11.1, 4.8 Hz, 1H), 3.49 (dd, *J* = 11.1, 4.5 Hz, 1H), 2.75–2.71 (m, 1H), 2.01–1.92 (m, 1H), 1.63 (dt, *J* = 11.4, 9.5 Hz, 1H), 1.06 (s, 9H), 0.86 (s, 9H), 0.00 (s, 3H), -0.02 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 152.4, 136.0, 134.3, 134.0, 131.0, 130.0, 129.9, 128.0, 127.9, 127.8, 126.7, 108.2, 72.4, 71.6, 62.7, 53.6, 43.7, 27.1, 26.0, 19.3, 18.3, -4.5, -4.7. HRMS (ESI): *m*/*z* calcd for C₂₉H₄₈NO₃Si₂⁺ [M + NH₄]⁺ 514.3167; found 514.3165.

(1*R*,3*R*,4*S*)-4-(*tert*-Butyldimethylsilyloxy)-3-hydroxymethyl-2-methylenecyclopentyl Benzoate (5k). $[α]_D^{25}$ -26.4 (*c* 1.0, CHCl₃). IR (ATR): 3503, 3064, 2954, 2929, 2885, 2856, 1718 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.10–8.04 (m, 2H), 7.61–7.53 (m, 1H), 7.49–7.40 (m, 2H), 5.66–5.61 (m, 1H), 5.37 (t, *J* = 2.4 Hz, 1H), 5.19 (t, *J* = 2.4 Hz, 1H), 4.19–4.10 (m, 1H), 3.86–3.80 (m, 2H), 2.81–2.71 (m, 1H), 2.64–2.55 (m, 1H), 1.83 (dt, *J* = 12.7, 8.4 Hz, 1H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 166.5, 147.7, 133.1, 130.3, 129.8, 128.5, 112.0, 74.2, 72.2, 62.5, 53.5, 40.5, 25.9, 18.0, -4.3, -4.8. HRMS (ESI): *m/z* calcd for C₂₀H₃₁O₄Si⁺ [M + H]⁺ 363.1986; found 363.1988.

Catalytic 5-Exo Cyclization of 4g. Strictly deoxygenated anhydrous THF (15 mL) was added to a mixture of IrCl(CO)(PPh₃)₂ (0.260 g, 0.34 mmol) and manganese powder (0.368 g, 6.70 mmol). A solution of 2,4,6-collidine (3.5 mL, 26.8 mmol) and 4g (1.000 g, 3.35 mmol) in strictly deoxygenated anhydrous THF (22 mL) was added at rt. TMSCl (1.7 mL, 13.4 mmol) was added followed by a solution of Cp₂TiCl₂ (0.167 g, 0.67 mmol) in strictly deoxygenated anhydrous THF (12 mL) and the mixture was stirred for 4 h under H_2 (4 bar) at rt. Water (5 mL) was added and the mixture was stirred for 10 min and filtered through Celite. The pad was washed with MTBE (20 mL) and the organic phases were combined and acidified to pH = 2 with 2 M HCl. The mixture was stirred for 15 min and the phases were separated. The organic phase was washed with H₂O (20 mL) and dried (Na₂SO₄). The solvent was removed and the resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 60:40 (gradient elution)] to give the title compound (5g) as a pale yellow oil (0.582 g, 58%).

((1R,3R,5Š)-5-Acetoxy-3-(*tert*-butyldimethylsilyloxy)-2methylenecyclopentyl)methyl 4-Nitrobenzoate (5I). NEt₃ (0.65 mL, 4.62 mol) was added dropwise to a solution of 5g (1.000 g, 3.33 mmol) and a catalytic amount of DMAP in anhydrous CH₂Cl₂ (9 mL) at 0 °C under N₂. A solution of *p*-nitrobenzoyl chloride (0.740 g, 3.99 mmol) in anhydrous CH₂Cl₂ (4 mL) was added dropwise at 0-5 °C. The mixture was allowed to warm to rt and was stirred for 2 h. Saturated NH₄Cl (10 mL) was added slowly and the mixture was stirred for 15 min. The mixture was partitioned and the organic phase was washed with H_2O and dried (Na_2SO_4). The solvent was removed and the resulting oily residue was purified by flash chromatography (silica gel, hexanes-AcOEt 90:10) to give the title compound (51) as white solid (1.102 g, 74% yield). Mp 83 °C. $[\alpha]_{D}^{25}$ -8.6 (c 1.0, CHCl₃). IR (ATR): 2981, 2959, 2944, 2884, 2858, 1730, 1713 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.31–8.13 (m, 4H), 5.27 (t, J = 2.3 Hz, 1H), 5.13 (t, J = 2.3 Hz, 1H), 5.05 (dt, J = 8.4, 6.6 Hz, 1H), 4.48 (m, 3H), 3.18-3.08 (m, 1H), 2.59-2.44 (m, 1H), 1.99 (s, 3H), 1.79-1.64 (m, 1H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H). ¹³C NMR (CDCl₂, 101 MHz): δ 170.9, 164.6, 150.7, 150.5, 135.5, 130.8, 123.7, 110.1, 73.2, 72.5, 66.3, 46.9, 40.5, 25.9, 21.2, 18.3, -4.5, -4.6. HRMS (ESI): m/z calcd for $C_{22}H_{32}NO_7Si^+$ [M + H]⁺ 450.1943; found 450.1947.

((1R,3R,5S)-5-Acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-Nitrobenzoate (5m). (+)-Camphorsulfonic acid ((+)-CSA, 0.034 g, 0.15 mmol) was added to a solution of 51 (0.660 g, 1.47 mmol) in anhydrous MeOH (7 mL) at rt under N₂. The mixture was stirred for 2 h and was then cooled to 0 °C and stirred for 1 h. The pH was adjusted to 6.5 by adding 1% NaHCO₃ solution. The MeOH was removed in vacuo and the aqueous layer was extracted with MTBE. The organic phase was dried (Na₂SO₄), the solvent was removed and the resulting oily residue was purified by flash chromatography (silica gel, hexanes-AcOEt 60:40) to give the title compound (5m) as a white solid (0.439 g, 89%). Mp 73 °C. $[\alpha]_D^{25}$ -32.7 (c 1.0, CHCl₃). IR (KBr): 3460, 3109, 3074, 3050, 2990, 2927, 1722 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.26-8.22 (m, 4H), 5.44 (bs, 1H), 5.25 (d, J = 1.5 Hz, 1H), 5.17 (q, J = 5.5 Hz, 1H), 4.56-4.54 (m, 1H), 4.52–4.43 (m, 1H), 4.42–4.30 (m, 1H), 3.21–3.18 (m, 1H), 2.53–2.49 (m, 1H), 2.02 (s, 3H), 1.85 (dt, J = 12.4, 5.5 Hz, 1H). ¹³C NMR (CDCl₃, 101 MHz): δ 170.6, 164.6, 151.3, 150.8, 135.4, 130.8, 123.8, 112.3, 74.8, 73.2, 65.9, 47.9, 40.1, 21.3. HRMS (ESI): *m*/*z* calcd for $C_{16}H_{21}N_2O_7^+$ [M + NH₄]⁺ 353.1343; found 353.1328.

((1R,3S,5S)-5-Acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2methylenecyclopentyl)methyl 4-Nitrobenzoate (13). A mixture of 2-amino-6-chloropurine (7.380 g, 43.54 mmol) and triphenylphosphine (11.400 g, 43.54 mmol) in anhydrous THF (927 mL) at rt under N₂ was stirred for 15 min. After cooling to -10 °C, diisopropyl azodicarboxylate (DIAD, 8.60 mL, 43.54 mmol) was added dropwise and the mixture was stirred for 10 min. A solution of 5m (7.300 g, 21.77 mmol) in anhydrous THF (160 mL) was added over 1 h. The mixture was stirred for 3 h at -10 °C and was then allowed to warm to rt, filtered and the residue was washed with THF (109 mL). The solvent was removed and the resulting oily residue was purified by crystallization from isopropanol (440 mL) to afford the title compound as a pale yellow solid (6.510 g, 61%). Mp 113 °C. $[\alpha]_{D}^{25}$ +9.8 (c 1.0, CHCl₃). IR (KBr): 3498, 3382, 3213, 3082, 2970, 1728, 1715 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz): δ 8.28 (dd, J = 20.6, 8.9 Hz, 4H), 7.80 (s, 1H), 5.58-5.40 (m, 2H), 5.35-5.30 (m, 1H), 4.91 (bs, 1H), 4.85 (dd, J = 11.4, 9.3 Hz, 1H), 4.62 (dd, J = 11.4, 6.3 Hz, 1H), 3.28–3.24 (m, 1H), 2.85 (ddd, J = 14.3, 10.6, 5.2 Hz, 1H), 2.42 (dd, J = 14.3, 8.1 Hz, 1H), 2.08 (s, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 170.3, 165.0, 158.9, 153.1, 151.8, 150.8, 146.2, 141.9, 135.2, 130.9, 125.9, 123.8, 113.6, 74.6, 65.9, 57.4, 48.7, 35.5, 21.3. HRMS (ESI): m/z calcd for $C_{21}H_{20}ClN_6O_6^+$ [M + H]⁺ 487.1127; found 487.1132.

((1*R*,3*S*,5*S*)-5-Acetoxy-3-(2-amino-6-oxo-1*H*-purin-9(6*H*)-yl)-2-methylenecyclopentyl)methyl 4-Nitrobenzoate (14). A solution of 13 (6.300 g, 12.94 mmol) in formic acid 80% (126 mL) at 50 °C under N₂ was stirred for 9 h. The solvent was removed, H₂O (72 mL) was added and the suspension was stirred for 18 h at rt. The suspension was filtered and the solid was dried to afford the title compound (14) as a yellow solid (5.590 g, 92%). Mp 282 °C. $[\alpha]_D^{25}$ +2.9 (*c* 1.0, DMSO). IR (KBr): 3408, 3315, 3210, 3110, 2934, 2868, 1728, 1706 cm^{-1.} ¹H NMR (DMSO- $d_{6^{\prime}}$ 400 MHz) δ: 11.08 (bs, 1H), 8.37 (d, *J* = 8.8 Hz, 2H), 8.24 (d, *J* = 8.8 Hz, 2H), 7.74 (s, 1H), 6.66 (bs, 2H), 5.42–5.35 (m, 1H), 5.35–5.31 (m, 1H), 5.27 (bs, 1H), 4.67 (bs, 1H), 4.59–4.55 (m, 2H), 3.17–3.10 (m, 1H), 2.70 (ddd, *J* = 13.6, 11.3, 5.3 Hz, 1H), 2.34–2.25 (m, 1H), 2.01 (s, 3H). ¹³C NMR (DMSO- $d_{6^{\prime}}$ 101 MHz) δ: 169.9, 164.3, 156.8, 153.5, 151.2, 150.3, 147.8, 136.1, 135.1, 130.7, 123.9, 116.5, 111.2, 74.1, 65.6, 55.2, 47.8, 35.2, 21.0. HRMS (ESI): *m*/*z* calcd for C₂₁H₂₁N₆O₇⁺ [M + H]⁺ 469.1466; found 469.1461.

2-Amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2methylenecyclopentyl)-1H-purin-6(9H)-one Monohydrate (1). A solution of MeONa (30%, 4.10 mL, 22.20 mmol) was added dropwise to a solution of 14 (5.200 g, 11.10 mmol) in anhydrous MeOH (40 mL) at rt under N2. The mixture was stirred for 30 min at rt and cooled to 0 °C. MTBE (52 mL) was added and the mixture was neutralized (pH = 7) with HCl. The phases were separated and the aqueous layer was extracted with MTBE (50 mL). The volume of the aqueous phase was reduced to 45 mL by distillation. The suspension was heated at 85 °C and was slowly cooled to rt and stirred for 15 h. After filtration the isolated solid was dried under vacuum to afford the title compound (1) as a white solid with a 6.5% water content (as determined by Karl Fischer titration) and 98.8% HPLC purity (2.370 g, 72% yield). This white solid 1^{5a} was recrystallized from water to afford 1 (2.102 g, 64% overall yield, 99.47% HPLC purity) with a 6.7% water content (as determined by Karl Fischer titration). Mp 248 °C. $[\alpha]_{D}^{25}$ +35.0 (c 0.4, H₂O). IR (ATR): 3445, 3361, 3296, 3175, 3113, 2951, 2858, 2626, 1709 cm⁻¹. ¹H NMR (DMSO- d_{6} , 400 MHz) δ : 10.59 (s, 1H), 7.66 (s, 1H), 6.42 (bs, 2H), 5.36 (ddt, J = 10.6, 7.8, 2.7 Hz, 1H), 5.10 (dd, J = 2.7, 2.2 Hz, 1H), 4.87 (d, J = 3.1 Hz, 1H), 4.84 (t, J = 5.3 Hz, 1H), 4.56 (t, J = 2.4 Hz, 1H), 4.23 (m, 1H), 3.53 (m, 2H), 2.52 (m, 1H), 2.22 (ddd, J = 12.6, 10.8, 4.6 Hz, 1H), 2.04 (ddt, J = 12.6, 7.7, 1.9 Hz, 1H). ¹³C NMR (DMSO- d_{6} , 101 MHz) δ : 156.9, 153.5, 151.5, 151.3, 136.0, 116.2, 109.3, 70.4, 63.1, 55.2, 54.1, 39.2. HRMS (ESI): m/z calcd for $C_{12}H_{16}N_5O_3^+$ [M + H]⁺ 278.1253; found 278.1262.

ASSOCIATED CONTENT

S Supporting Information

¹H and ¹³C NMR spectra of **1**, **3a-e**, **4b-k**, **5b**, **5g-h**, **5k-m**, **6**, **7a-f**, **13** and **14**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel.: +34 934021248. Fax: +34 933397878. E-mail: jfarras@ub.edu, xariza@ub.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the Spanish Ministerio de Educación y Ciencia (Grants PET2008-0209 and IPT-2011-1005-900000).

REFERENCES

(1) *Hepatitis B*; Fact sheet No. 204; World Health Organization, July 2012. http://www.who.int/mediacentre/factsheets/fs204/en/index. html (accessed March 22, 2013).

(2) Dienstag, J. L. N. Engl. J. Med. 2008, 359, 1486-1500.

(3) Scott, L. J.; Keating, G. M. Drugs 2009, 69, 1003-1033.

(4) (a) Zahler, R.; Slusarchyk, W. A. Eur. Pat. EP0481754 B1, August 20, 1997. (b) Bisacchi, G. S.; Sundeen, J. E. WO9809964 A1, August 26, 1997.

(5) (a) Bisacchi, G. S.; Chao, S. T.; Bachard, C.; Daris, J. P.; Innaimo, S.; Jacobs, G. A.; Kocy, O.; Lapointe, P.; Martel, A.; Merchant, Z.; Slusarchyk, W. A.; Sundeen, J. E.; Young, M. G.; Colonno, R.; Zahler, R. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 127–132. (b) Innaimo, S. F.;

Seifer, M.; Bisacchi, G. S.; Standring, D. N.; Zahler, R.; Colonno, R. J. Antimicrob. Agents Chemother. **1997**, 41, 1444–1448.

(6) (a) Gu, Y.; Cai, R.; Sun, X.; Zhu, H.; Zhao, Y. (Suzhou Well-Bridge Biological Technology Co., Ltd., Peop. Rep. China) CN102924454, A, February 13, 2013. (b) Jung, I. H.; Jang, M. S.; Kim, G. N. (Sungwun Pharmacopia Co., Ltd., S. Korea; Hanseo Chemical Co., Ltd.) KR2012091971, A, August 20, 2012. (c) Chen, H.; Jin, Y. (Shanghai Yonghong Industry Group Chemical Technology Co., Ltd., Peop. Rep. China) CN102477036, A, May 30, 2012. (d) Zheng, Z. (Ausun Pharmatech Co. Ltd., Peop. Rep. China) WO2012006964, A1, January 19, 2012. (e) Alberico, D.; Gorin, B.; Beharrilall, R.; Dixon, C.; Clayton, J.; Rexon, V. WO2011150513, A1, December 8, 2011. (f) Xu, K.; Wang, J.; Zhong, D.; Li, Z.; Hao, J. (Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd., Peop. Rep. China) CN102225938, A, October 26, 2011. (g) Hu, T.-C.; Huang, H.-T. (Scinopharm Taiwan Ltd.) US2011201809, A1, August 18, 2011. (h) Li, G.; Qiu, B.; Yang, X.; Chen, S. (Fujian Cosunter Pharmaceutical Co., Ltd., Peop. Rep. China) CN102491960, A, Jun 13, 2012. (i) Lee, J. H.; Park, G. S.; Kim, J. H.; Choi, T. J.; Lee, J. E.; Han, J. H.; Bang, H. J.; Jung, S. Y.; Chang, Y. K.; Lee, G. S., Kim, M. S. (Hanmi Holdings Co., Ltd., S. Korea) WO2011046303, A2, April 21 2011. (j) Lee, J.; Park, G.-S.; Kim, J. H.; Lee, J. E.; Park, C. H.; Choi, T. J.; Park, E.-J.; Kim, C. K.; Lim, E. J.; Chang, Y.-K.; Lee, G. S. (Hanmi Pharm. Ind. Co., Ltd., S. Korea) WO2010074534, A2, July 1, 2010. (k) Fang, Y.; Li, C.; Yin, F. (Hande Pharma Ltd., Peop. Rep. China) CN101891741, A, November 24, 2010. (1) Lei, X.; Lin, G.; Zeng, Y. (Fudan University, Peop. Rep. China) CN101781301, A, July 21, 2010. (m) Zhou, Z.; Wei, X.; Xu, X.; Chen, H. (Shanghai Pharmaceutical Co., Ltd., Peop. Rep. China) CN101759698, A, June 30, 2010. (n) Zeng, Y.; Wang, Z.; Gao, D.; Xu, Z. (Anhui Biochem. United Pharmaceutical Co., Ltd., Peop. Rep. China) CN101531660, A, September 16, 2009. (o) Liu, K.; Li, Y.; Wang, H.; Gao, X.; Tao, X.; Zhao, P.; Luo, G.; Tan, Y.; Yin, H.; Zhang, J. (Leadingpharm Laboratories Inc., Peop. Rep. China) CN 101337962, A, January 07, 2009. (p) Zhao, J.; Li, X.; Zhu, J.; Lou, J.; Zhou, X.; Cai, X.; Dong, Y.; Ye, X.; Zhang, M.; Xu, Z.; Wei, W.; Liu, W. (Hangzhou Shengyou Pharmaceutical Technology Co., Ltd., Peop. Rep. China; Tianjin Taipu Medicine Science and Technology Development Co., Ltd.; Shanghai Guochuang Pharmaceutical Co., Ltd.) CN101210015, A, July 02, 2008. (q) Kang, H. Fujian Guangshengtang Pharmaceutical Co., Ltd., Peop. Rep. China) CN101182322, A, May 21, 2008. (r) Yan, H. CN101148450, A, March 26, 2008. (s) Yuan, J.; Zhang, X.; Liu, F.; Zhang, K.; Ye, X.; Ge, Y. (Jiangsu Chia-Tai Tianqing Pharmaceutical Co., Ltd., Peop. Rep. China; Brightgene Bio-Medical Tech Ltd.) CN101130542, A, February 27, 2008. (t) Jiang, W.; Wang, W.; Hu, Y. (SFFT Developing Co., Ltd., Peop. Rep. China) CN101050216, A, October 10, 2007. (u) Chen, Y.; Han, S.; Yin, J.; Sun, T.; Cai, W.; Zhang, Y.; Ruan, G.; Zhu, Q.; Wang, X. (Shanghai Yangfan Pharmaceutical Technology Co., Ltd., Peop. Rep. China; Jiangsu Yangtze River Pharmaceutical Group) CN101012228, A, August 08, 2007. (v) Zhang, L.; Zeng, Z.; Yang, L.; Guo, L. (Shanghai Zhongxia Chemical Co., Ltd., Peop. Rep. China) CN1861602, A, November 15, 2006. (w) Zhou, M. X.; Reiff, E. A.; Vemishetti, P.; Pendri, Y. R.; Singh, A. K.; Prasad, S. J.; Dhokte, U. P.; Qian, X.; Mountford, P.; Hartung, K. B.; Sailes, H. (Bristol-Myers Squibb Company, USA), WO2005118585, A1, December 15, 2005. (x) Pendri, Y. R.; Chen, C. H.; Patel, S. S.; Evans, J. M.; Liang, J.; Kronenthal, D. R.; Powers, G. L.; Prasad, S. J.; Bien, J. T.; Shi, Z.; Patel, R. N.; Chan, Y. Y.; Rijhwani, S. K.; Singh, A. K.; Wang, S.; Stojanovic, M.; Polniaszek, R.; Lewis, C.; Thottathil, J.; Krishnamurty, D.; Zhou, M. X.; Vemishetti, P. (Bristol-Myers Squibb Company, USA), WO2004052310, A3, December 10, 2003.

(7) Guo, L. W.; Xiao, Y. J.; Yang, L. P. Chin. Chem. Lett. 2006, 17, 907–910.

(8) (a) Ying, L.; Wang, Z. (Shanghai Changsen Pharmaceutical Co., Ltd., Peop. Rep. China) CN102863444, A, January 9, 2013. (b) Fan, M.; Mao, J.; Si, B.; Feng, J. (Shanghai Changsen Pharmaceutical Co., Ltd., Peop. Rep. China) CN102417506, A, April 18, 2012. (c) Liu, X.; Jiao, X.; Wu, Q.; Tian, C.; Li, R.; Xie, P. *Tetrahedron Lett.* **2012**, *53*,

The Journal of Organic Chemistry

3805–3807. (d) Zhou, B.; Li, Y. Tetrahedron Lett. 2012, 53, 502–504.
(e) Rawal, R. K.; Singh, U. S.; Gadthula, S.; Chu, C. K. Curr. Protoc. Nucleic Acid Chem. 2011, 47, 14.7.1–14.7.17.

(9) This work has been partially reported in the following patents:
(a) Bartra, M.; Berenguer, R.; Velasco, J.; Ariza, J.; Farràs, J.; García, J.
(Esteve Química, S.A., Spain) WO2012085209, A1, June 28, 2012.
(b) Berenguer, R.; Badia, L.; Gasanz, Y.; Velasco, J.; Ariza, X. (Esteve Química, S.A., Spain) PCT/EP2012/073438, November 24, 2011.

(10) For recent reviews on the synthesis of carbocyclic nucleosides, see: (a) Boutureira, O.; Matheu, M. I.; Díaz, Y.; Castillón, S. Chem. Soc. Rev. 2013, DOI: 10.1039/C3CS00003F. (b) Matyugina, E. S.; Khandazhinskaya, A. L.; Kochetkov, S. N. Russ. Chem. Rev. 2012, 81, 729–746. (c) Wang, J.; Rawal, R. K.; Chu, C. K. Recent Advances in Carbocyclic Nucleosides: Synthesis and Biological Activity. In Medicinal Chemistry of Nucleic Acids; Zhang, L.-H., Xi, Z., Chattopadhyaya, J., Eds.; Wiley & Sons: Hoboken, NJ, 2011; pp 1–100.

(11) (a) Nugent, W. A.; RajanBabu, T. V. J. Am. Chem. Soc. 1988, 110, 8561-8562. (b) RajanBabu, T. V.; Nugent, W. A. J. Am. Chem. Soc. 1994, 116, 986-997. For reviews, see: (c) Rossi, B.; Prosperini, S.; Pastori, N.; Clerici, A.; Punta, C. Molecules 2012, 17, 14700-14732. (d) Cuerva, J. M.; Justicia, J.; Oller-López, J. L.; Bazdi, B.; Oltra, J. E. Mini-Rev. Org. Chem. 2006, 3, 23-35. (e) Cuerva, J. M.; Justicia, J.; Oller-López, J. L.; Oller-López, J. Cuerva, J. M.; Justicia, J.; Oller-López, J. L.; Oller-López, J. L.; Oller-López, J. Cuerva, J. M.; Justicia, J.; Oller-López, J. L.; Oller, J. E. Top. Curr. Chem. 2006, 264, 63-91. (f) Barrero, A. F.; Quílez del Moral, J. F.; Sánchez, E. M.; Arteaga, J. F. Eur, J. Org. Chem. 2006, 1627-1641.

(12) Ziegler, F. E.; Sarpong, M. A. *Tetrahedron* **2003**, *59*, 9013–9018. (13) For a recent review, see: Ariza, X.; Garcia, J.; Romea, P.; Urpí, F. Synthesis **2011**, 2175–2191.

(14) Paterson, I.; Goodman, J. M.; Lister, M. A.; Schumann, R. C.; McClure, C. K.; Norcross, R. D. *Tetrahedron* **1990**, *46*, 4663–4684.

(15) Paterson, I.; Perkins, M. V. Tetrahedron 1996, 52, 1811–1834 and references therein.

(16) (a) Gansäuer, A.; Pierobon, M.; Bluhm, H. Angew. Chem., Int. Ed. **1998**, 37, 101–103. (b) Andreas Gansäuer, A.; Bluhm, H.; Pierobon, M. J. Am. Chem. Soc. **1998**, 120, 12849–12859.

(17) Barrero, A. F.; Rosales, A.; Cuerva, J. M.; Oltra, J. E. Org. Lett. 2003, 5, 1935–1938.

(18) Gansäuer, A.; Otte, M.; Shi, L. J. Am. Chem. Soc. 2011, 133, 416-417.

Article